---
title: "Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286404245.md"
description: "Corvus Pharmaceuticals presented Phase 1 data for soquelitinib, demonstrating durable drug-free remissions and a favorable safety profile. The trial involved 72 patients, showing dose-dependent efficacy with significant results in Cohorts 3 and 4. Cohort 3 achieved 50% EASI-75 and 25% IGA 0/1, while Cohort 4 reached 75% EASI-75 and 33% IGA 0/1, with no rebound effects noted. Adverse events were comparable to placebo, all Grade 1-2. Biomarker data indicated effective ITK inhibition, supporting the drug's potential."
datetime: "2026-05-14T11:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286404245.md)
  - [en](https://longbridge.com/en/news/286404245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286404245.md)
---

# Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety

**Corvus Pharmaceuticals reported Phase 1 soquelitinib data showing durable, drug-free remissions and favorable safety.**

**Key Highlights:**

-   Phase 1 trial (72 patients) showed dose-dependent efficacy and additional benefit with longer treatment.
-   Cohort 3 (200 mg BID): 50% EASI-75, 8% EASI-90, 25% IGA 0/1; responses durable through 90-day follow-up.
-   Cohort 4 (200 mg BID, 8 weeks): 75% EASI-75, 25% EASI-90, 33% IGA 0/1; no rebound or rescue meds in 30-day follow-up.
-   Safety profile comparable to placebo: AEs in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no SAEs.
-   Biomarker data support ITK inhibition: reduced Th2/Th17 markers, increased persistent Tregs, and JAK‑STAT pathway modulation.

Original SEC Filing: Corvus Pharmaceuticals, Inc. \[ CRVS \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CRVS.US](https://longbridge.com/en/quote/CRVS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra]]>](https://longbridge.com/en/news/286601439.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)